Showing 1901-1910 of 2152 results for "".
- Santen Acquires Eyevance Pharmaceuticalhttps://modernod.com/news/santen-acquires-eyevance-pharmaceutical/2478289/In a move to enter the US pharmaceuticals market and expand its global presence, Santen announced it has acquired Eyevance Pharmaceutical for $225 million in cash. In the deal, Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, will acquire all of the outstanding shares of Ey
- Sight Sciences Presents Additional Results of OLYMPIA Study of Signs and Symptoms of Dry Eye Disease Using TearCarehttps://modernod.com/news/sight-sciences-presents-additional-results-of-olympia-study-of-signs-and-symptoms-of-dry-eye-disease-using-tearcare/2478263/Sight Sciences announced further favorable results of a trial evaluating a single treatment of TearCare for the treatment of signs and symptoms of dry eye disease in patients with meibomian gland dysfunction. TearCare is currently marketed for the application of localized heat to the eyelids for
- Health Canada Authorizes Enspryng for Canadians Living with Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/health-canada-authorizes-enspryng-for-canadians-living-with-neuromyelitis-optica-spectrum-disorder/2478219/Roche Canada announced that Health Canada has granted market authorization for Enspryng (satralizumab) as monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent patients who are anti-aqu
- Topcon Announces the US Launch of Aladdin-Mhttps://modernod.com/news/topcon-announces-the-us-launch-of-aladdin-m/2478217/Topcon Healthcare announced that it has launched its new Aladdin-M instrument in the US market. Aladdin-M combines corneal topography, pupillometry, and optical biometry to enable objective measurement of corneal curvature, pupil dynamics, and axial length metrics. The all-in-one Aladdin-M
- Safer and More Effective Glaucoma Surgical Options Will Drive Surgery Device Treatment Penetration Over Next Five Yearshttps://modernod.com/news/safer-and-more-effective-glaucoma-surgical-options-will-drive-surgery-device-treatment-penetration-over-next-five-years/2478181/Expanding use of surgical devices in patients with all stages of glaucoma will increase the role of surgery in the glaucoma treatment paradigm over the next 5 years, according to a Market Scope report. There are four FDA-approved minimally invasive glaucoma surgery (MIGS) stents in the US:
- BVI Launches IPure Aspheric Monofocal IOL in the UShttps://modernod.com/news/bvi-launches-ipure-aspheric-monofocal-iol-in-the-us/2478172/BVI has entered the US IOL market with the launch of the IPure preloaded aspheric monofocal IOL. BVI says the IPure is the first and only preloaded aspheric monofocal IOL available in both a 1-piece and 3-piece design. IPure’s patented aspheric optic design provides high contract, hi
- Johnson & Johnson Vision Launches Tecnis Synergy and Tecnis Eyhance IOLs in Canadahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-synergy-and-tecnis-eyhance-iols-in-canada/2478160/Johnson & Johnson Vision announced Health Canada approval and July availability of its Tecnis Synergy and Tecnis Eyhance IOLs to the Canadian market. The Tecnis Synergy, originally launched in Europe in September 2019, delivers continuous high-cont
- Serum Institute to Produce COVID-19 Vaccines From AstraZeneca, Novavaxhttps://modernod.com/news/serum-institute-to-produce-covid-19-vaccines-from-astrazeneca-novavax/2478139/The Serum Institute of India (SII) said it will produce coronavirus vaccines from AstraZeneca and Novavax, making them available for procurement, if they gain marketing approval, at a ceiling price of $3 per dose. SII noted that it will use funding from Gavi, The Vaccine Alliance and the Bill &am
- AstraZeneca Takes COVID-19 Vaccine to China With BioKangtai Deal for 200M-Dose Capacity by 2021https://modernod.com/news/astrazeneca-takes-covid-19-vaccine-to-china-with-biokangtai-deal-for-200m-dose-capacity-by-2021/2478134/Last week China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. That has changed, according to a FiercePharma
- Eyenuk Announces FDA Clearance for EyeArt Autonomous AI System for Diabetic Retinopathy Screeninghttps://modernod.com/news/eyenuk-announces-fda-clearance-for-eyeart-autonomous-ai-system-for-diabetic-retinopathy-screening/2478123/Eyenuk announced it has received 510(k) clearance by the FDA to market its EyeArt autonomous AI System for diabetic retinopathy. EyeArt is indicated for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopa